StreetAlpha
13F holdings · Q3 2026

Gilead Sciences

Foster City, CA · files as Gilead Sciences, Inc.
Know the moment Gilead Sciences filesYou follow Gilead Sciences An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Holdings as of Sep 30, 2026Filed Nov 5, 2026Next filing due Feb 15, 2027CIK 882095

Gilead Sciences reported 5 stocks worth $1.5B in its 13F filing for Q3 2026, filed Nov 5, 2026. Its largest holdings are RCUS (55.5%), LKFT (34.2%) and ASMB (8.0%).

Latest filing: what Gilead Sciences did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
0 new0 added0 trimmed0 sold outBought about $0 · sold about $0
New 0

None

Added 0

None

Trimmed 0

None

Sold out 0

None

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$1.5B−11.2% vs last quarter
Stocks held50 new · 0 sold out
Top 5 weight100.0%very concentrated
Turnover0%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
RCUS
Arcus Biosciences Inc
$812M55.5%31.4MNo change8 of 8
2
LKFT
Galapagos NV
$501M34.2%16.7MNo change8 of 8
3
ASMB
Assembly Biosciences Inc
$117M8.0%5MNo change8 of 8
4
KYTX
Kyverna Therapeutics Inc
$28.1M1.9%4.1MNo change8 of 8
5
XLO
Xilio Therapeutics Inc
$5.9M0.4%650KNo change8 of 8

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Reported value

last 8 quarters
$1.6BQ4 '24
$1.2BQ1 '25
$1.3BQ2 '25
$1.8BQ3 '25
$1.9BQ4 '25
$2.1BQ1 '26
$1.6BQ2 '26
$1.5BQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 5, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Gilead Sciences 13F FAQ

What does Gilead Sciences own?

Gilead Sciences reported 5 stocks worth $1.5B in its 13F filing for Q3 2026, filed Nov 5, 2026. Its largest holdings are RCUS (55.5%), LKFT (34.2%) and ASMB (8.0%). The table above lists every position in the filing (the top 10 without an account).

What did Gilead Sciences buy and sell in Q3 2026?

Compared with Q2 2026: 0 new positions, 0 added to, 0 trimmed and 0 sold out.

When will Gilead Sciences file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Gilead Sciences's portfolio worth?

The Q3 2026 filing reports $1.5B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.